Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.66 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.66 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.66 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ATR | Q13535 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | FADS1 | O60427 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30338961 | 1.00 | CHRNB2 (0.66) | CHRNB2CHRNB4CHRNA3CHRNA4NPC1 | |
| SCHEMBL16713265 | 0.85 | CHRNB2 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA4NPC1 | |
| SCHEMBL30339171 | 0.83 | MEN1 (0.69) | CHRNB2CHRNB4CHRNA3CHRNA4NPC1 | |
| SCHEMBL1961500 | 0.83 | MEN1 (0.69) | CHRNB2CHRNB4CHRNA3CHRNA4NPC1 | |
| SCHEMBL8375299 | 0.81 | CHRNB2 (0.64) | CHRNB2CHRNB4CHRNA3CHRNA4NPC1 | |
| SCHEMBL14314287 | 0.80 | ALDH1A1 (0.54) | CHRNB2CHRNB4CHRNA3CHRNA4NPC1 | |
| SCHEMBL25063312 | 0.78 | SMN1; SMN2 (0.68) | CHRNB2CHRNB4CHRNA3CHRNA4NPC1 | |
| SCHEMBL30339211 | 0.78 | SMN1; SMN2 (0.68) | CHRNB2CHRNB4CHRNA3CHRNA4NPC1 | |
| SCHEMBL24073677 | 0.78 | CHRNB2 (0.61) | CHRNB2CHRNB4CHRNA3CHRNA4NPC1 | |
| SCHEMBL30142760 | 0.78 | CHRNB2 (0.61) | CHRNB2CHRNB4CHRNA3CHRNA4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| CN-116472292-A | Modified proteins and protein degrading agents | 上海睿跃生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-02-23 | — | — | US | disclosed |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-02-23 | — | — | US | disclosed |
| WO-2022270987-A1 | AURKA SELECTIVE DEGRADATION INDUCING COMPOUND | (주) 업테라 | 2022-12-29 | — | — | WO | disclosed |
| WO-2021239117-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI) , INC. (CN) | 2021-12-02 | — | — | WO | disclosed |
| EP-3185868-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | Salk Institute for Biological Studies (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016033100-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-03-03 | — | — | WO | disclosed |
| US-9238628-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM Biosicences Australia PTY LTD (US) | 2016-01-19 | — | — | US | disclosed |
| US-20140011803-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2014-01-09 | — | — | US | disclosed |
| EP-1317433-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020495-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | CHRNB2 4530/4885CHRNB4 4698/4885CHRNA3 4788/4885 |
| US-20140011803-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | CHRNB2 4884/4885CHRNB4 4885/4885CHRNA3 4877/4885 |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | CHRNB2 4530/4885CHRNB4 4698/4885CHRNA3 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.